Managing hypercalcaemia and hypocalcaemia in cancer patients

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 3, 2013, Pages 265-271

  Fallah Rad, Nazanin ^a   Ross Morton, A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; Denosumab; Hypercalcaemia; Hypocalcaemia; Malignancy; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; MAGNESIUM; MONOCLONAL ANTIBODY; VITAMIN D;

BLOOD; FLUID THERAPY; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; METHODOLOGY; NEOPLASM; PATHOPHYSIOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; DIPHOSPHONATES; FLUID THERAPY; HUMANS; HYPERCALCEMIA; HYPOCALCEMIA; MAGNESIUM; NEOPLASMS; VITAMIN D;

EID: 84887908626     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283640f5f     Document Type: Review

References (20)

1. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol 2010; 5:S23-30.
2. Soyfoo MS, Brenner K, Paesmans M, Body JJ. Nonmalignant causes of Hypercalcaemia in cancer patients: a frequent and neglected occurrence. Support Cancer Care 2013; 21:1415-1419.
3. Stewart AF. Hypercalcaemia associated with cancer. N Engl J Med 2005; 352:373-379.
4. Wysolmerski JJ. Parathyroid hormone related peptide: An update. J Clin Endocrinol Metab 2012; 97:2947-2956.
5. Yamashita T, Takahashi N, Udagawa N. New roles of osteoblasts involved in osteoclast differentiation. World J Orthop 2012; 3:175-181.
6. Baldassarre RL, Chang DC, Brummund KT, Bouvet M. Predictors of hypocalcemia after thyroidectomy: results from the nationwide inpatient sample. ISRN Surg 2012; 2012:838614; doi:10.5402/2012/838614.
7. Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletalrelated events in cancer patients. Support Care Cancer 2012; 20:1353-1360.
8. Segal E, Felder S, Haim N, et al. Vitamin D deficiency in oncology patients-an ignored condition: Impact on hypocalcemia and quality of life. Isr Med Assoc J 2012; 14:607-612.
9. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for Hypercalcaemia: an unproven yet common practice. Ann Intern Med 2008; 149:259-263.
10. Fleisch H. Development of bisphosphonates. Breast Cancer Res Commun 2002; 4:30-34.
11. Sabry NA, Habib EE. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study. Med Oncol 2011; 28:584-590.
12. Boikos SA, Hammers H-J. Denosumab for the treatment of bisphosphonaterefractory Hypercalcaemia. J Clin Oncol 2012; 30:e229.
13. Hu MI, Gucalp R, Isogna K, et al., 53rd American Society of Hematology Meeting and Exposition. Denosumab for treatment of Hypercalcaemia of malignancy in patients with solid tumours or hematological malignancies refractory to IV bisphosphonates: a single-arm multicenter study. San Diego, California; 2011; https://ash.confex.com/ash/2011/webprogram/Paper39343.html.
14. Saidak Z, Mentaverri M, Brown EM. The role of the calcium-sensing receptor in the development and progression of cancer. Endocrine Reviews 2009; 30:178-195.
15. Bech A, Smolders K, Telting D, de Boer H. Cinacalcet for Hypercalcaemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related peptide. Case Rep Oncol 2012; 5:1-8.
16. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007; 92:3803-3808.
17. Wang CC, Chen YC, Shiang JC, et al. Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Amer J of Emerg Med 2009; 27:1174e1-1174e3.
18. Cvitkovic F, Armand J-P, Tubiana-Hulin M, et al. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related Hypercalcaemia. Cancer J 2006; 12:47-53.
19. LeGrand SB. Modern management of malignant Hypercalcaemia. Amer J Hospice and Palliative Med 2011; 28:515-517.
20. Fong J, Khan A. Hypocalcemia. Canadian Fam Phys 2012; 58:158-162.